Our portfolio company, ALTOIDA, secured financing from Hikma Ventures, the venture capital arm of Hikma Pharmaceuticals PLC.
ALTOIDA is a health technology firm that uses active digital biomarkers and cutting-edge technology in artificial intelligence and augmented reality to classify patients’ risk of mild cognitive impairment due to Alzheimer’s disease and drive better clinical outcomes for brain diseases.
The financing will be used to further expand ALTOIDA’s presence in the US, Japan, Europe and Brazil. It follows the company’s USD 6.3million Series A round closed in early 2019.
Alpana congratulates the whole ALTOIDA’s team for this closing.